Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Low Cost Biosensor to Be Based on Printing Technologies

By LabMedica International staff writers
Posted on 14 Sep 2011
Scientists intend to use the latest printing technologies to develop a low cost biosensor capable of diagnosing a range of health conditions.

Living antibodies will be placed into a suitable ink and then printed onto a compatible substrate or material to form a disposable sensor, capable of being mass-produced at low cost. More...
The printed array of antibodies speeds up the testing process while reducing the expertise and complexity of equipment needed--introducing the possibility of hand held electronic scanners and far quicker diagnosis.

Antibody based assays are routinely used to detect specific medical conditions but use of these tests is limited because they need to be carried out in laboratories by highly skilled technicians, which is costly and time consuming.

The team developing the new technique is led by Prof. Tim Claypole, head of Swansea University's Welsh Center of Printing and Coating (Wales, United Kingdom). Prof. Claypole said the project is at the forefront of international research and represents a major advance in the printing of biomedical sensors.

“The availability of low cost, disposable sensor technology is a core requirement for the early diagnosis of disease. The use of antibodies as sensors targeted to detect specific human conditions is regarded as one of the next major advances in health care.

“Volume printing is also the most practical method to achieve low cost disposable sensor technology. This will take innovation from the bench to the bedside and develop the tools and technologies to move the process of diagnosis forward and bring it into the surgery and home.”

In addition to allowing some aspects of patient care to be moved from the hospital or laboratory to the GP surgery, the new biosensor technology could also be useful in emergency situations and in remote areas.

The project is supported by the Welsh Government's Academic Expertise for Business (A4B), an EU funded initiative to stimulate and encourage collaboration between educational institutions and industry.

The initial focus will be developing a proof of concept device that will open opportunities to develop antibody sensors to diagnose a broad range of health conditions.

Related Links:

Swansea University's Welsh Center of Printing and Coating
Welsh Government's Academic Expertise for Business




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.